ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pentetic Acid

Its studies are mostly in Diphtheria, led by GlaxoSmithKline.

Drug pagePentetic Acid: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 13, 20261 company-led study, 1 open or runningNext primary completion: Nov 23, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 3since May 13, 2026May 13, 2026Nov 23, 2026phase 3 · NCT07596199

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 13, 2026First study: phase 3 study in DiphtheriaFirst studyNCT07596199 · 102 enrolled · Japan

Ahead

  1. Nov 23, 2026Primary completion: phase 3 study in DiphtheriaNCT07596199

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07596199Diphtheria · Japan3Active, not recruitingNov 23, 2026102

How it is read

Names in the registry

  • “dTpa”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.